Razuprotafib Does Not Improve Microcirculatory Perfusion Disturbances nor Renal Edema in Rats on Extracorporeal...

Area of Science:

• Cardiovascular Research
• Inflammation and Immunology
• Medical Devices

Background:

• Extracorporeal membrane oxygenation (ECMO) is life-saving but causes complications like systemic inflammation and tissue edema.
• Endothelial hyperpermeability, driven by factors like VE-PTP, contributes to ECMO-related organ damage.
• Microvascular dysfunction is a key complication of extracorporeal circulation (ECC).

Purpose of the Study:

• To investigate if inhibiting vascular endothelial protein tyrosine phosphatase (VE-PTP) with Razuprotafib mitigates ECC-induced microvascular dysfunction.
• To assess the impact of Razuprotafib on systemic inflammation and organ edema during ECC.
• To evaluate Razuprotafib's effect on pulmonary function and inflammation post-ECC.

Main Methods:

• Rats underwent ECC with Razuprotafib or placebo treatment, or a sham procedure.
• Capillary perfusion was assessed using intravital microscopy.
• Kidney edema, inflammatory markers (TNFα, IL-6), angiopoietins, and pulmonary function (PaO2/FiO2 ratio) were measured.

Main Results:

• Razuprotafib did not improve capillary perfusion or reduce kidney edema following ECC.
• Razuprotafib suppressed TNFα increase and improved the PaO2/FiO2 ratio, reducing pulmonary inflammation.
• Circulating inflammatory markers and specific gene expressions related to endothelial permeability were largely unaffected.

Conclusions:

• Razuprotafib did not ameliorate ECC-induced microcirculatory disturbances or renal edema.
• The drug demonstrated a potential benefit in reducing pulmonary inflammation and improving oxygenation post-ECC.
• VE-PTP inhibition may have specific, context-dependent effects on ECC-related complications.